Literature DB >> 28804149

Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer.

Meghan J Garrett1, J Aubrey Waddell1,1, Dominic A Solimando2.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net. The information presented in this review is based on published data and clinical expertise and includes information not included in the product labeling. Incorporation of such published data provides a more robust assessment of the drugs and assists pharmacists in evaluation of orders for off-label use of these agents.

Entities:  

Year:  2017        PMID： 28804149      PMCID： PMC5551630          DOI： 10.1177/0018578717715353

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  29 in total

1.  Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.

Authors:  Axel Grothey; Daniel A Nikcevich; Jeff A Sloan; John W Kugler; Peter T Silberstein; Todor Dentchev; Donald B Wender; Paul J Novotny; Umesh Chitaley; Steven R Alberts; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 3.  Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

Authors:  Erick Gamelin; Laurence Gamelin; Laura Bossi; Stefan Quasthoff
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

4.  Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

Authors:  Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

5.  Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Authors:  Chris H Takimoto; Scot C Remick; Sunil Sharma; Sridhar Mani; Ramesh K Ramanathan; James Doroshow; Anne Hamilton; Daniel Mulkerin; Martin Graham; Graham F Lockwood; Percy Ivy; Merrill Egorin; Barbara Schuler; Denis Greenslade; Andrew Goetz; Ronald Knight; Rebecca Thomas; Brian P Monahan; William Dahut; Jean L Grem
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

6.  A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.

Authors:  Nikol Snoeren; Emile E Voest; Andre M Bergman; Otilia Dalesio; Henk M Verheul; Rob A E M Tollenaar; Joost R M van der Sijp; Sander B Schouten; Inne H M Borel Rinkes; R van Hillegersberg
Journal:  BMC Cancer       Date:  2010-10-11       Impact factor: 4.430

7.  Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG).

Authors:  Lambros Vamvakas; Alexios Matikas; Athanasios Karampeazis; Dora Hatzidaki; Stelios Kakolyris; Charalampos Christophylakis; Ioannis Boukovinas; Aris Polyzos; Vassilis Georgoulias; John Souglakos
Journal:  BMC Cancer       Date:  2014-04-22       Impact factor: 4.430

8.  Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.

Authors:  Christopher G C A Jackson; Katrina Sharples; Paul I Thompson; Anne O'Donnell; Bridget Anne Robinson; David J Perez; Jacqui Adams; Richard Isaacs; Sanjeev Deva; Victoria A Hinder; Michael P Findlay
Journal:  BMC Cancer       Date:  2014-10-02       Impact factor: 4.430

9.  Hypersensitivity reactions related to oxaliplatin (OHP).

Authors:  G Brandi; M A Pantaleo; C Galli; A Falcone; A Antonuzzo; P Mordenti; M C Di Marco; G Biasco
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

10.  Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.

Authors:  Yoshinori Munemoto; Mitsuro Kanda; Keiichiro Ishibashi; Taishi Hata; Michiya Kobayashi; Junichi Hasegawa; Mutsumi Fukunaga; Akinori Takagane; Toshio Otsuji; Yasuhiro Miyake; Michitaka Nagase; Junichi Sakamoto; Masaki Matsuoka; Koji Oba; Hideyuki Mishima
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.